|
Identifying the role of apolipoprotein A-I in prostate cancer
Jing Wang1,2, Ling-Fan Xu3, Cheng Liu2, Tao Huang2, Chao-Zhao Liang3, Yi-Dong Fan1
1 Department of Urology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
2 Department of Urologic Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China
3 Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
Correspondence Address:
Chao-Zhao Liang,
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022
China
Yi-Dong Fan,
Department of Urology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012
China
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/aja.aja_92_20 PMID: 33586698
|
|
Although localized prostate cancer (PCa) can be cured by prostatectomy and radiotherapy, the development of effective therapeutic approaches for advanced prostate cancer, including castration-resistant PCa (CRPC) and neuroendocrine PCa (NEPC), is lagging far behind. Identifying a novel prognostic and diagnostic biomarker for early diagnosis and intervention is an urgent clinical need. Here, we report that apolipoprotein A-I (ApoA-I), the major component of high-density lipoprotein (HDL), is upregulated in PCa based on both bioinformatics and experimental evidence. The fact that advanced PCa shows strong ApoA-I expression reflects its potential role in driving therapeutic resistance and disease progression by reprogramming the lipid metabolic network of tumor cells. Molecularly, ApoA-I is regulated by MYC, a frequently amplified oncogene in late-stage PCa. Altogether, our findings have revealed a novel indicator to predict prognosis and recurrence, which would benefit patients who are prone to progress to metastasis or even NEPC, which is the lethal subtype of PCa.
|
Search Pubmed for